Multiple protein kinases in tumor cells and tumor microenvironment

Multiple protein kinases in tumor cells and the tumor microenvironment (TME) represent a diverse set of enzymes that facilitate cancer progression through both cell-intrinsic and extrinsic pathways. In tumor cells, kinases such as RAF, KIT, and FLT3 drive uncontrolled proliferation and survival (Source: Nature Reviews Cancer, 2020). Simultaneously, kinases within the TME, including VEGFR, PDGFR, and FGFR, regulate angiogenesis, fibroblast activation, and the recruitment of immunosuppressive cells (Source: Journal of Hematology & Oncology, 2019). Multi-kinase inhibitors (MKIs) are designed to target these various proteins concurrently, providing a comprehensive approach to disrupting the tumor's life-support system and overcoming resistance mechanisms associated with single-target therapies (Source: NIH/NCI). This broad inhibitory profile is particularly effective in complex, heterogeneous malignancies like hepatocellular carcinoma and renal cell carcinoma. However, the simultaneous inhibition of multiple pathways often results in significant systemic toxicities, such as hypertension and dermatological reactions, which require careful clinical management (Source: StatPearls, 2023). By targeting both the neoplastic cells and their surrounding niche, these agents aim to achieve more durable clinical responses than highly selective inhibitors in specific therapeutic contexts.

Other names

Multi-kinase targetsTumor and TME kinasesPan-kinase targetsKinome targets in cancer

Inhibition of the catalytic activity of multiple protein kinases by competing with ATP for the binding site, thereby disrupting intracellular signaling cascades in both tumor cells and supporting cells within the microenvironment (Source: PubMed PMID: 31514351).